PURDUE PHARMA L.P.

Remarks in House

Drugs: address issues relative to composition, marketing, and regulatory approval of OxyContin, H5532 [1AU]

FDA: review classification of painkiller OxyContin for treatment of moderate pain and deny approval for generic versions, H5530 [1AU]